-
1
-
-
80052269271
-
Does microvascular disease predict macrovascular events in type 2 diabetes?
-
Rosenson RS, Fioretto P, Dodson PM. Does microvascular disease predict macrovascular events in type 2 diabetes? Atherosclerosis 2011;218:13-8.
-
(2011)
Atherosclerosis
, vol.218
, pp. 13-18
-
-
Rosenson, R.S.1
Fioretto, P.2
Dodson, P.M.3
-
2
-
-
77953051113
-
Cardiovascular disease in diabetes
-
Bloomgarden ZT. Cardiovascular disease in diabetes. Diabetes Care 2010;33:e49-54.
-
(2010)
Diabetes Care
, vol.33
-
-
Bloomgarden, Z.T.1
-
3
-
-
79952600167
-
Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors
-
Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med 2011;171:404-10.
-
(2011)
Arch Intern Med
, vol.171
, pp. 404-410
-
-
Wannamethee, S.G.1
Shaper, A.G.2
Whincup, P.H.3
Lennon, L.4
Sattar, N.5
-
4
-
-
0032511580
-
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
-
UK Prospective Diabetes Study Group.
-
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
-
(1998)
BMJ
, vol.317
, pp. 703-713
-
-
-
5
-
-
77951704587
-
Effects of combination lipid therapy in type 2 diabetes mellitus
-
ACCORD Study Group
-
ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
-
(2010)
N Engl J Med
, vol.362
, pp. 1563-1574
-
-
Ginsberg, H.N.1
Elam, M.B.2
Lovato, L.C.3
Crouse, J.R.4
Leiter, L.A.5
Linz, P.6
Friedewald, W.T.7
Buse, J.B.8
Gerstein, H.C.9
Probstfield, J.10
Grimm, R.H.11
Ismail-Beigi, F.12
Bigger, J.T.13
Goff, D.C.14
Cushman, W.C.15
Simons-Morton, D.G.16
Byington, R.P.17
-
6
-
-
38049033935
-
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis
-
Cholesterol Treatment Trialists' (CTT) Collaborators
-
Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25.
-
(2008)
Lancet
, vol.371
, pp. 117-125
-
-
Kearney, P.M.1
Blackwell, L.2
Collins, R.3
Keech, A.4
Simes, J.5
Peto, R.6
Armitage, J.7
Baigent, C.8
-
7
-
-
38949210220
-
Effect of a multifactorial intervention on mortality in type 2 diabetes
-
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91.
-
(2008)
N Engl J Med
, vol.358
, pp. 580-591
-
-
Gaede, P.1
Lund-Andersen, H.2
Parving, H.H.3
Pedersen, O.4
-
8
-
-
56249123656
-
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient
-
Residual Risk Reduction Initiative (R3I)
-
Fruchart JC, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P; Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 2008;5:319-35.
-
(2008)
Diab Vasc Dis Res
, vol.5
, pp. 319-335
-
-
Fruchart, J.C.1
Sacks, F.M.2
Hermans, M.P.3
Assmann, G.4
Brown, W.V.5
Ceska, R.6
Chapman, M.J.7
Dodson, P.M.8
Fioretto, P.9
Ginsberg, H.N.10
Kadowaki, T.11
Lablanche, J.M.12
Marx, N.13
Plutzky, J.14
Reiner, Z.15
Rosenson, R.S.16
Staels, B.17
Stock, J.K.18
Sy, R.19
Wanner, C.20
Zambon, A.21
Zimmet, P.22
more..
-
9
-
-
33846623798
-
Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets
-
Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007;115:518-33.
-
(2007)
Circulation
, vol.115
, pp. 518-533
-
-
Brown, J.D.1
Plutzky, J.2
-
10
-
-
78349283454
-
Peroxisome proliferator-activated receptor alpha target genes
-
Rakhshandehroo M, Knoch B, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res 2010;2010:612089.
-
(2010)
PPAR Res
, vol.2010
, pp. 612089
-
-
Rakhshandehroo, M.1
Knoch, B.2
Muller, M.3
Kersten, S.4
-
11
-
-
1842295133
-
Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors
-
DiRenzo J, Soderstrom M, Kurokawa R, Ogliastro MH, Ricote M, Ingrey S, Horlein A, Rosenfeld MG, Glass CK. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol Cell Biol 1997;17:2166-76.
-
(1997)
Mol Cell Biol
, vol.17
, pp. 2166-2176
-
-
DiRenzo, J.1
Soderstrom, M.2
Kurokawa, R.3
Ogliastro, M.H.4
Ricote, M.5
Ingrey, S.6
Horlein, A.7
Rosenfeld, M.G.8
Glass, C.K.9
-
12
-
-
0034951170
-
Peroxisome-proliferator-activated receptors as physiological sensors of fatty acid metabolism: molecular regulation in peroxisomes
-
Latruffe N, Cherkaoui Malki M, Nicolas-Frances V, Jannin B, Clemencet MC, Hansmannel F, Passilly-Degrace P, Berlot JP. Peroxisome-proliferator-activated receptors as physiological sensors of fatty acid metabolism: molecular regulation in peroxisomes. Biochem Soc Trans 2001;29(Pt 2):305-9.
-
(2001)
Biochem Soc Trans
, vol.29
, Issue.PART 2
, pp. 305-309
-
-
Latruffe, N.1
Cherkaoui Malki, M.2
Nicolas-Frances, V.3
Jannin, B.4
Clemencet, M.C.5
Hansmannel, F.6
Passilly-Degrace, P.7
Berlot, J.P.8
-
13
-
-
84868607245
-
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects
-
Rosenson RS, Wright RS, Farkouh M, Plutzky J. Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am Heart J 2012;164:672-80.
-
(2012)
Am Heart J
, vol.164
, pp. 672-680
-
-
Rosenson, R.S.1
Wright, R.S.2
Farkouh, M.3
Plutzky, J.4
-
14
-
-
23644456172
-
Therapeutic roles of peroxisome proliferator-activated receptor agonists
-
Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005;54:2460-70.
-
(2005)
Diabetes
, vol.54
, pp. 2460-2470
-
-
Staels, B.1
Fruchart, J.C.2
-
15
-
-
19244365650
-
Thiazolidinediones
-
Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
-
(2004)
N Engl J Med
, vol.351
, pp. 1106-1118
-
-
Yki-Jarvinen, H.1
-
16
-
-
0030047806
-
Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
-
Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996;137:354-66.
-
(1996)
Endocrinology
, vol.137
, pp. 354-366
-
-
Braissant, O.1
Foufelle, F.2
Scotto, C.3
Dauca, M.4
Wahli, W.5
-
17
-
-
1542723720
-
Prediction of PPAR-alpha ligand-mediated physiological changes using gene expression profiles
-
Frederiksen KS, Wulff EM, Sauerberg P, Mogensen JP, Jeppesen L, Fleckner J. Prediction of PPAR-alpha ligand-mediated physiological changes using gene expression profiles. J Lipid Res 2004;45:592-601.
-
(2004)
J Lipid Res
, vol.45
, pp. 592-601
-
-
Frederiksen, K.S.1
Wulff, E.M.2
Sauerberg, P.3
Mogensen, J.P.4
Jeppesen, L.5
Fleckner, J.6
-
18
-
-
20144373625
-
Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner
-
Arakawa R, Tamehiro N, Nishimaki-Mogami T, Ueda K, Yokoyama S. Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol 2005;25:1193-7.
-
(2005)
Arterioscler Thromb Vasc Biol
, vol.25
, pp. 1193-1197
-
-
Arakawa, R.1
Tamehiro, N.2
Nishimaki-Mogami, T.3
Ueda, K.4
Yokoyama, S.5
-
19
-
-
79957482363
-
Peroxisome proliferator-activated receptor-a activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway
-
Nakaya K, Tohyama J, Naik SU, Tanigawa H, MacPhee C, Billheimer JT, Rader DJ. Peroxisome proliferator-activated receptor-a activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway. Arterioscler Thromb Vasc Biol 2011;31:1276-82.
-
(2011)
Arterioscler Thromb Vasc Biol
, vol.31
, pp. 1276-1282
-
-
Nakaya, K.1
Tohyama, J.2
Naik, S.U.3
Tanigawa, H.4
MacPhee, C.5
Billheimer, J.T.6
Rader, D.J.7
-
20
-
-
0033542873
-
Medical significance of peroxisome proliferator-activated receptors
-
Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999;354:141-8.
-
(1999)
Lancet
, vol.354
, pp. 141-148
-
-
Vamecq, J.1
Latruffe, N.2
-
22
-
-
84856080783
-
The cardiovascular effects of peroxisome proliferator-activated receptor agonists
-
Friedland SN, Leong A, Filion KB, Genest J, Lega IC, Mottillo S, Poirier P, Reoch J, Eisenberg MJ. The cardiovascular effects of peroxisome proliferator-activated receptor agonists. Am J Med 2012;125:126-33.
-
(2012)
Am J Med
, vol.125
, pp. 126-133
-
-
Friedland, S.N.1
Leong, A.2
Filion, K.B.3
Genest, J.4
Lega, I.C.5
Mottillo, S.6
Poirier, P.7
Reoch, J.8
Eisenberg, M.J.9
-
23
-
-
84875166950
-
Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies
-
Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, Murad MH. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med 2013;30:1026-32.
-
(2013)
Diabet Med
, vol.30
, pp. 1026-1032
-
-
Ferwana, M.1
Firwana, B.2
Hasan, R.3
Al-Mallah, M.H.4
Kim, S.5
Montori, V.M.6
Murad, M.H.7
-
24
-
-
84870268099
-
The risk of bladder cancer in korean diabetic subjects treated with pioglitazone
-
Song SO, Kim KJ, Lee BW, Kang ES, Cha BS, Lee HC. The risk of bladder cancer in korean diabetic subjects treated with pioglitazone. Diabetes Metab J 2012;36:371-8.
-
(2012)
Diabetes Metab J
, vol.36
, pp. 371-378
-
-
Song, S.O.1
Kim, K.J.2
Lee, B.W.3
Kang, E.S.4
Cha, B.S.5
Lee, H.C.6
-
25
-
-
84868702636
-
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
-
Tenenbaum A, Fisman EZ. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc Diabetol 2012;11:140.
-
(2012)
Cardiovasc Diabetol
, vol.11
, pp. 140
-
-
Tenenbaum, A.1
Fisman, E.Z.2
-
26
-
-
0037453718
-
Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity
-
Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003;113:159-70.
-
(2003)
Cell
, vol.113
, pp. 159-170
-
-
Wang, Y.X.1
Lee, C.H.2
Tiep, S.3
Yu, R.T.4
Ham, J.5
Kang, H.6
Evans, R.M.7
-
27
-
-
0346849699
-
The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells
-
Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GE. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol 2003;17:2477-93.
-
(2003)
Mol Endocrinol
, vol.17
, pp. 2477-2493
-
-
Dressel, U.1
Allen, T.L.2
Pippal, J.B.3
Rohde, P.R.4
Lau, P.5
Muscat, G.E.6
-
28
-
-
28044452217
-
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
-
FIELD study investigators.
-
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
-
(2005)
Lancet
, vol.366
, pp. 1849-1861
-
-
Keech, A.1
Simes, R.J.2
Barter, P.3
Best, J.4
Scott, R.5
Taskinen, M.R.6
Forder, P.7
Pillai, A.8
Davis, T.9
Glasziou, P.10
Drury, P.11
Kesäniemi, Y.A.12
Sullivan, D.13
Hunt, D.14
Colman, P.15
d'Emden, M.16
Whiting, M.17
Ehnholm, C.18
Laakso, M.19
-
29
-
-
26844579239
-
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
-
FIELD Study Investigators.
-
Scott R, Best J, Forder P, Taskinen MR, Simes J, Barter P, Keech A; FIELD Study Investigators. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol 2005;4:13.
-
(2005)
Cardiovasc Diabetol
, vol.4
, pp. 13
-
-
Scott, R.1
Best, J.2
Forder, P.3
Taskinen, M.R.4
Simes, J.5
Barter, P.6
Keech, A.7
-
30
-
-
64749095070
-
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
-
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators
-
Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32:493-8.
-
(2009)
Diabetes Care
, vol.32
, pp. 493-498
-
-
Scott, R.1
O'Brien, R.2
Fulcher, G.3
Pardy, C.4
D'Emden, M.5
Tse, D.6
Taskinen, M.R.7
Ehnholm, C.8
Keech, A.9
-
31
-
-
34250785602
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods
-
ACCORD Study Group
-
ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99(12A):21i-33i.
-
(2007)
Am J Cardiol
, vol.99
, Issue.12 A
-
-
Buse, J.B.1
Bigger, J.T.2
Byington, R.P.3
Cooper, L.S.4
Cushman, W.C.5
Friedewald, W.T.6
Genuth, S.7
Gerstein, H.C.8
Ginsberg, H.N.9
Goff, D.C.10
Grimm, R.H.11
Margolis, K.L.12
Probstfield, J.L.13
Simons-Morton, D.G.14
Sullivan, M.D.15
-
32
-
-
0023232216
-
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
-
Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
-
(1987)
N Engl J Med
, vol.317
, pp. 1237-1245
-
-
Frick, M.H.1
Elo, O.2
Haapa, K.3
Heinonen, O.P.4
Heinsalmi, P.5
Helo, P.6
Huttunen, J.K.7
Kaitaniemi, P.8
Koskinen, P.9
Manninen, V.10
Maenpaa, H.11
Malkonen, M.12
Manttari, M.13
Norola, S.14
Pasternack, A.15
Pikkarainen, J.16
Romo, M.17
Sjoblom, T.18
Nikkila, E.A.19
-
33
-
-
0033527030
-
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
-
Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8.
-
(1999)
N Engl J Med
, vol.341
, pp. 410-418
-
-
Rubins, H.B.1
Robins, S.J.2
Collins, D.3
Fye, C.L.4
Anderson, J.W.5
Elam, M.B.6
Faas, F.H.7
Linares, E.8
Schaefer, E.J.9
Schectman, G.10
Wilt, T.J.11
Wittes, J.12
-
35
-
-
79952986434
-
Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation
-
Tomizawa A, Hattori Y, Inoue T, Hattori S, Kasai K. Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metabolism 2011;60:513-22.
-
(2011)
Metabolism
, vol.60
, pp. 513-522
-
-
Tomizawa, A.1
Hattori, Y.2
Inoue, T.3
Hattori, S.4
Kasai, K.5
-
36
-
-
0038325699
-
Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism
-
Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003;62:572-5.
-
(2003)
Ann Rheum Dis
, vol.62
, pp. 572-575
-
-
Takahashi, S.1
Moriwaki, Y.2
Yamamoto, T.3
Tsutsumi, Z.4
Ka, T.5
Fukuchi, M.6
-
37
-
-
0034521404
-
Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories
-
Milionis HJ, Elisaf MS. Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories. Curr Med Res Opin 2000;16:164-70.
-
(2000)
Curr Med Res Opin
, vol.16
, pp. 164-170
-
-
Milionis, H.J.1
Elisaf, M.S.2
-
38
-
-
67349188030
-
Emerging role of PPAR ligands in the management of diabetic nephropathy
-
Balakumar P, Arora MK, Singh M. Emerging role of PPAR ligands in the management of diabetic nephropathy. Pharmacol Res 2009;60:170-3.
-
(2009)
Pharmacol Res
, vol.60
, pp. 170-173
-
-
Balakumar, P.1
Arora, M.K.2
Singh, M.3
-
40
-
-
84860527078
-
Fibrates: therapeutic potential for diabetic nephropathy?
-
Kouroumichakis I, Papanas N, Zarogoulidis P, Liakopoulos V, Maltezos E, Mikhailidis DP. Fibrates: therapeutic potential for diabetic nephropathy? Eur J Intern Med 2012;23:309-16.
-
(2012)
Eur J Intern Med
, vol.23
, pp. 309-316
-
-
Kouroumichakis, I.1
Papanas, N.2
Zarogoulidis, P.3
Liakopoulos, V.4
Maltezos, E.5
Mikhailidis, D.P.6
-
41
-
-
84858339432
-
Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?
-
Balakumar P, Kadian S, Mahadevan N. Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney? Pharmacol Res 2012;65:430-6.
-
(2012)
Pharmacol Res
, vol.65
, pp. 430-436
-
-
Balakumar, P.1
Kadian, S.2
Mahadevan, N.3
-
42
-
-
37549035027
-
Diabetic nephropathy: mechanisms of renal disease progression
-
Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S, Danesh FR. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood) 2008;233:4-11.
-
(2008)
Exp Biol Med (Maywood)
, vol.233
, pp. 4-11
-
-
Kanwar, Y.S.1
Wada, J.2
Sun, L.3
Xie, P.4
Wallner, E.I.5
Chen, S.6
Chugh, S.7
Danesh, F.R.8
-
43
-
-
58049134293
-
Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat
-
Balakumar P, Chakkarwar VA, Singh M. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol Cell Biochem 2009;320:149-62.
-
(2009)
Mol Cell Biochem
, vol.320
, pp. 149-162
-
-
Balakumar, P.1
Chakkarwar, V.A.2
Singh, M.3
-
44
-
-
33646508121
-
PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice
-
Park CW, Zhang Y, Zhang X, Wu J, Chen L, Cha DR, Su D, Hwang MT, Fan X, Davis L, Striker G, Zheng F, Breyer M, Guan Y. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 2006;69:1511-7.
-
(2006)
Kidney Int
, vol.69
, pp. 1511-1517
-
-
Park, C.W.1
Zhang, Y.2
Zhang, X.3
Wu, J.4
Chen, L.5
Cha, D.R.6
Su, D.7
Hwang, M.T.8
Fan, X.9
Davis, L.10
Striker, G.11
Zheng, F.12
Breyer, M.13
Guan, Y.14
-
45
-
-
78951474167
-
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
-
Fenofibrate Intervention and Event Lowering in Diabetes Study investigators.
-
Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC; Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011;54:280-90.
-
(2011)
Diabetologia
, vol.54
, pp. 280-290
-
-
Davis, T.M.1
Ting, R.2
Best, J.D.3
Donoghoe, M.W.4
Drury, P.L.5
Sullivan, D.R.6
Jenkins, A.J.7
O'Connell, R.L.8
Whiting, M.J.9
Glasziou, P.P.10
Simes, R.J.11
Kesäniemi, Y.A.12
Gebski, V.J.13
Scott, R.S.14
Keech, A.C.15
-
46
-
-
0036364909
-
Fenofibrate increases creatininemia by increasing metabolic production of creatinine
-
Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002;92:536-41.
-
(2002)
Nephron
, vol.92
, pp. 536-541
-
-
Hottelart, C.1
El Esper, N.2
Rose, F.3
Achard, J.M.4
Fournier, A.5
-
47
-
-
14844292088
-
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS)
-
DAIS Investigators.
-
Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G; DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005;45:485-93.
-
(2005)
Am J Kidney Dis
, vol.45
, pp. 485-493
-
-
Ansquer, J.C.1
Foucher, C.2
Rattier, S.3
Taskinen, M.R.4
Steiner, G.5
-
48
-
-
0034575092
-
Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients
-
Nagai T, Tomizawa T, Nakajima K, Mori M. Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J Atheroscler Thromb 2000;7:91-6.
-
(2000)
J Atheroscler Thromb
, vol.7
, pp. 91-96
-
-
Nagai, T.1
Tomizawa, T.2
Nakajima, K.3
Mori, M.4
-
49
-
-
0031437734
-
Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?
-
Smulders YM, van Eeden AE, Stehouwer CD, Weijers RN, Slaats EH, Silberbusch J. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest 1997;27:997-1002.
-
(1997)
Eur J Clin Invest
, vol.27
, pp. 997-1002
-
-
Smulders, Y.M.1
van Eeden, A.E.2
Stehouwer, C.D.3
Weijers, R.N.4
Slaats, E.H.5
Silberbusch, J.6
-
50
-
-
36049001784
-
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial
-
FIELD study investigators.
-
Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d'Emden MC, Crimet DC, O'Connell RL, Colman PG; FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97.
-
(2007)
Lancet
, vol.370
, pp. 1687-1697
-
-
Keech, A.C.1
Mitchell, P.2
Summanen, P.A.3
O'Day, J.4
Davis, T.M.5
Moffitt, M.S.6
Taskinen, M.R.7
Simes, R.J.8
Tse, D.9
Williamson, E.10
Merrifield, A.11
Laatikainen, L.T.12
d'Emden, M.C.13
Crimet, D.C.14
O'Connell, R.L.15
Colman, P.G.16
-
51
-
-
77954654472
-
Effects of medical therapies on retinopathy progression in type 2 diabetes
-
ACCORD Study Group; ACCORD Eye Study Group
-
ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-44.
-
(2010)
N Engl J Med
, vol.363
, pp. 233-244
-
-
Chew, E.Y.1
Ambrosius, W.T.2
Davis, M.D.3
Danis, R.P.4
Gangaputra, S.5
Greven, C.M.6
Hubbard, L.7
Esser, B.A.8
Lovato, J.F.9
Perdue, L.H.10
Goff, D.C.11
Cushman, W.C.12
Ginsberg, H.N.13
Elam, M.B.14
Genuth, S.15
Gerstein, H.C.16
Schubart, U.17
Fine, L.J.18
-
52
-
-
84866031914
-
Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus
-
Hamren B, Ohman KP, Svensson MK, Karlsson MO. Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus. J Clin Pharmacol 2012;52:1317-27.
-
(2012)
J Clin Pharmacol
, vol.52
, pp. 1317-1327
-
-
Hamren, B.1
Ohman, K.P.2
Svensson, M.K.3
Karlsson, M.O.4
-
53
-
-
34948873034
-
Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes
-
GALLANT 9 Study Group.
-
Ratner RE, Parikh S, Tou C; GALLANT 9 Study Group. Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes. Diab Vasc Dis Res 2007;4:214-21.
-
(2007)
Diab Vasc Dis Res
, vol.4
, pp. 214-221
-
-
Ratner, R.E.1
Parikh, S.2
Tou, C.3
-
54
-
-
26844565049
-
Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo
-
Oleksiewicz MB, Thorup I, Nielsen HS, Andersen HV, Hegelund AC, Iversen L, Guldberg TS, Brinck PR, Sjogren I, Thinggaard UK, Jørgensen L, Jensen MB. Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo. Toxicol Pathol 2005;33:552-60.
-
(2005)
Toxicol Pathol
, vol.33
, pp. 552-560
-
-
Oleksiewicz, M.B.1
Thorup, I.2
Nielsen, H.S.3
Andersen, H.V.4
Hegelund, A.C.5
Iversen, L.6
Guldberg, T.S.7
Brinck, P.R.8
Sjogren, I.9
Thinggaard, U.K.10
Jørgensen, L.11
Jensen, M.B.12
-
55
-
-
42249084078
-
Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event
-
Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR. Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event. Toxicol Pathol 2008;36:218-31.
-
(2008)
Toxicol Pathol
, vol.36
, pp. 218-231
-
-
Long, G.G.1
Reynolds, V.L.2
Lopez-Martinez, A.3
Ryan, T.E.4
White, S.L.5
Eldridge, S.R.6
-
56
-
-
33745957332
-
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study
-
Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006;29:1016-23.
-
(2006)
Diabetes Care
, vol.29
, pp. 1016-1023
-
-
Kendall, D.M.1
Rubin, C.J.2
Mohideen, P.3
Ledeine, J.M.4
Belder, R.5
Gross, J.6
Norwood, P.7
O'Mahony, M.8
Sall, K.9
Sloan, G.10
Roberts, A.11
Fiedorek, F.T.12
DeFronzo, R.A.13
-
57
-
-
28144451163
-
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus
-
Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581-6.
-
(2005)
JAMA
, vol.294
, pp. 2581-2586
-
-
Nissen, S.E.1
Wolski, K.2
Topol, E.J.3
-
58
-
-
77954969340
-
Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus
-
Cavender MA, Lincoff AM. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs 2010;10:209-16.
-
(2010)
Am J Cardiovasc Drugs
, vol.10
, pp. 209-216
-
-
Cavender, M.A.1
Lincoff, A.M.2
-
59
-
-
67649839953
-
Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
-
Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009;374:126-35.
-
(2009)
Lancet
, vol.374
, pp. 126-135
-
-
Henry, R.R.1
Lincoff, A.M.2
Mudaliar, S.3
Rabbia, M.4
Chognot, C.5
Herz, M.6
-
60
-
-
84867139643
-
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes
-
Wilding JP. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. Diabetes Obes Metab 2012;14:973-82.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 973-982
-
-
Wilding, J.P.1
|